Moderna begins trails in cancer treatment vaccine

Key Concepts

• mRNA Platform: Moderna's core technology for developing vaccines and therapeutics.
• Cost Cutting: Moderna's current strategic focus to improve operational efficiency and achieve break-even.
• Oncology: Cancer treatment, identified as a future growth driver for Moderna.
• Rare Diseases: Another area of focus for Moderna's mRNA platform.
• COVID-19 Vaccine: Moderna's most famous product, though its sales are declining.
• Flu Vaccine: Moderna is exploring combining COVID-19 and flu vaccines.
• Immunotherapies: A class of cancer treatments that harness the immune system.
• PD-1 Inhibitors (e.g., Keytruda): A type of immunotherapy that blocks a protein that prevents the immune system from attacking cancer cells.
• Antibody Drug Conjugates (ADCs): Cancer therapies that combine antibodies with cytotoxic drugs.
• Cellular Therapies: Cancer treatments involving the modification of a patient's own cells.
• Alliance with Merck: A significant partnership for Moderna in oncology research.

Moderna's Strategic Shift and Future Prospects

Moderna, a US pharmaceutical company, has experienced a significant stock decline of approximately 50% over the past year. The company is currently prioritizing cost-cutting measures to improve operational efficiency and achieve a projected break-even point by 2028. Beyond cost management, Moderna is strategically shifting its focus towards oncology and rare diseases as the next key drivers for its messenger RNA (mRNA) platform.

Research and Development in Oncology

While Moderna is optimistic about the long-term potential of its mRNA platform in oncology, the development of cancer treatments is expected to take considerable time to yield significant results. The company has an alliance with Merck, which is considered a major positive. This partnership has shown promising data, particularly in melanoma, dating back several years. However, expanding the platform's applicability to a wider range of diseases and tumor types will require further development and time.

Jeff Mechum, managing director in biotech pharma equity research at City, holds a neutral rating on Moderna's shares. He notes that while Moderna's research on cancer treatments is promising, it will take time to bear fruit. He characterizes Moderna's mRNA platform, when combined with PD-1 inhibitors like Merck's Keytruda, as potentially additive rather than synergistic to existing immunotherapies.

The Oncology Market Landscape

The oncology market is described as multifaceted and challenging, not in terms of entry barriers, but due to the complexity of cancer itself and the competitive landscape. Existing treatments include highly effective immunotherapies that reprogram the immune system to recognize tumors, such as those incorporating IO (immuno-oncology) components from companies like Merck and Bristol Myers Squibb. The market also features other innovations like antibody drug conjugates (ADCs) and cellular therapies. Mechum views the mRNA platform as a potential addition to this crowded but promising field, which has seen significant disruption and meaningful changes.

COVID-19 Vaccine Performance and Future Strategies

Moderna's COVID-19 vaccine, while instrumental in its rise, is no longer the sole focus. The narrative has shifted, and sales of the COVID-19 vaccine have been impacted by uncertainty in US federal government policy, particularly a perceived decrease in top-down mandates from the Trump administration.

Interestingly, Moderna's newest COVID-19 vaccine is reportedly being manufactured in Canada. This move is seen as a natural outcome of the company's efforts to improve operational efficiencies and identify regions offering the highest return on investment (ROI) or cost savings. Mechum advises against over-interpreting this from a tariff perspective.

Looking ahead, Moderna is exploring the combination of its COVID-19 vaccine with a flu vaccine. This dual-asset approach, leveraging an annual, seasonal component, could gain traction in the coming years.

Comparative Analysis with Peers

When comparing Moderna to its peers like Pfizer and Merck, Mechum highlights that while Moderna and Pfizer-BioNTech were prolific in delivering massive quantities of COVID-19 vaccines, the challenge for Moderna lies in its "encore" – its next major success. BioNTech, a peer, has made significant strides in oncology and achieved a much higher valuation. Moderna is still in a transition phase, moving towards oncology and rare diseases, which are expected to be positive developments.

Key Arguments and Perspectives

• Moderna's current focus is on cost-cutting and operational efficiency. This is a necessary step to stabilize the company and achieve its 2028 break-even target.
• Oncology and rare diseases represent the future growth engines for Moderna's mRNA platform. While promising, these areas require substantial development time.
• The alliance with Merck is a significant positive for Moderna's oncology efforts.
• The oncology market is competitive but ripe for innovation. Moderna's mRNA platform can be additive to existing treatments.
• COVID-19 vaccine sales are declining due to policy shifts and market saturation.
• Combining COVID-19 and flu vaccines is a potential near-term strategy for Moderna.
• Moderna is in a transition phase, aiming to replicate its COVID-19 success in new therapeutic areas.

Conclusion

Moderna is navigating a critical transition period. While its COVID-19 vaccine remains a significant product, the company is strategically pivoting towards oncology and rare diseases, leveraging its mRNA platform. Cost-cutting is a primary immediate objective. The alliance with Merck in oncology offers a promising avenue, though significant development timelines are anticipated. The competitive landscape in oncology necessitates innovation, and Moderna's platform is seen as a potentially additive component. The company's future success hinges on its ability to translate its mRNA expertise into impactful treatments beyond its initial COVID-19 vaccine triumph.